Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
3.180
-0.060 (-1.85%)
May 13, 2026, 9:30 AM EDT - Market open
Exicure Employees
Exicure had 8 employees as of December 31, 2025. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change
1
Growth
14.29%
Revenue / Employee
n/a
Profits / Employee
-$618,250
Market Cap
20.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | 1 | 14.29% |
| Mar 31, 2025 | 8 | 3 | 60.00% |
| Dec 31, 2024 | 7 | 1 | 16.67% |
| Sep 30, 2024 | 6 | 0 | - |
| Jun 30, 2024 | 5 | -2 | -28.57% |
| Mar 31, 2024 | 5 | -4 | -44.44% |
| Dec 31, 2023 | 6 | -7 | -53.85% |
| Sep 30, 2023 | 6 | -31 | -83.78% |
| Jun 30, 2023 | 7 | -32 | -82.05% |
| Mar 31, 2023 | 9 | -31 | -77.50% |
| Dec 31, 2022 | 13 | -34 | -72.34% |
| Sep 30, 2022 | 37 | -40 | -51.95% |
| Jun 30, 2022 | 39 | -39 | -50.00% |
| Mar 31, 2022 | 40 | -26 | -39.39% |
| Dec 31, 2021 | 47 | -16 | -25.40% |
| Sep 30, 2021 | 77 | 20 | 35.09% |
| Jun 30, 2021 | 78 | 31 | 65.96% |
| Mar 31, 2021 | 66 | 23 | 53.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| Quince Therapeutics | 38 |
| Longeveron | 38 |
| Curis | 24 |
| OSR Holdings | 22 |
| SeaStar Medical Holding | 17 |
| Lantern Pharma | 16 |
| Lipocine | 14 |
XCUR News
- 20 days ago - Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) - GlobeNewsWire
- 5 weeks ago - Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions - GlobeNewsWire
- 6 weeks ago - Exicure, Inc. Reports Full Year 2025 Financial Results - GlobeNewsWire
- 3 months ago - Exicure announces publication of results from Phase 2 study of burixafor - TheFly
- 3 months ago - Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - GlobeNewsWire
- 4 months ago - Exicure to present data from burixafor Phase 2 trial at 2026 Tandem Meetings - TheFly
- 4 months ago - Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings - GlobeNewsWire
- 5 months ago - Exicure presents topline data from burixafor combination trial - TheFly